BETHESDA, Md., Sept. 15 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President and CEO, Dr. Christian Itin, will present at the 16th Annual NewsMakers in the Biotech Industry Conference on September 16, 2009 in New York City. A simultaneous webcast of the event will be available on the company's website at www.micromet-inc.com.
Forum: 16th Annual NewsMakers in the Biotech Industry Conference Date: Wednesday, September 16, 2009 Time: 11:00 am to 11:25 am U.S. Eastern Time Place: Millennium Broadway Hotel New York City, New York Webcast: www.micromet-inc.com
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include Sanofi-Aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.
This release contains certain forward-looking statements that involve risk
|SOURCE Micromet, Inc.|
Copyright©2009 PR Newswire.
All rights reserved